Drug Discovery

Great British Pounds, Investment
#ABPI #Drug discovery #UK #UK economy

UK payment rate for new medicines drops to 14.5% in 2026  

The 2026 payment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) will be 14.5%, down from a record 22.5% in 2025, the UK government has announced.   This news follows the recent announcement of the UK-US trade agreement… Read More

#News

Biomarkers concept
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: Accelerate your research in complex biological systems

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Stem cells
#Assays #Drug development #Drug discovery #iPSC-derived cells #Neuroscience

Technical Guide: Introducing the Brain-Chip R1

A new Technical Guide is now available from Emulate entitled ‘Characterization of the Brain-Chip R1: A First-in-Class, Isogenic Model of the Human Neurovascular Unit‘. Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial-like phenotype Maintains resting-state glia and a tight,… Read More

#News

#Assays #Drug development #Drug discovery #iPSC-derived cells #Neuroscience

Introducing the Brain-Chip R1: A new era for human-relevant BBB & NVU research

Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial-like phenotype Maintains resting-state glia and a tight, stable barrier throughout a four-day experimental window Features a streamlined, 12-day direct-to-chip workflow with no pre-plating or expansion steps, enabling robust and reproducible performance… Read More

#Resources #Technical Notes

#Artificial intelligence (AI) #Automation #Drug discovery #Webinar

Webinar: Gain a realistic view of what AI can do now for biotech R&D

AI has reached a turning point in biotech. Real-world scientific agents are beginning to automate the repetitive tasks that slow down research, and transform how we think about extracting insights from scientific data. In this webinar on… Read More

Webinar date:
Supported by Benchling
#News

CAR-T therapy for leukaemia
#ASH 2025 #Clinical trials #Drug discovery

CytoAgents announces positive preliminary data at ASH

Biotechnology company CytoAgents has presented preliminary safety data from its Phase Ib/IIa clinical trial of its lead drug candidate CTO1681. CTO1681 is an oral, small molecule immune modulator that uses a novel approach to prevent and mitigate both inflammation in the tumour microenvironment as well as toxicity frequently seen with… Read More

#News

Weight loss concept
#Clinical trials #Drug discovery #Obesity

Lilly begins obesity trial in the UK  

The first patient visit for Lilly’s five-year clinical trial assessing the company’s type-2 diabetes and weight-loss drug tirzepatide has taken place.  The SURMOUNT-REAL UK trial will last for five years and will assess the long-term effectiveness of tirzepatide on obesity outcomes when given in primary care settings. Taking place in Greater… Read More

#News

#Drug discovery

Ebook: Foundations of biospecimen success

Advances in biospecimen science are resolving long-standing challenges that have historically hindered research quality, reproducibility, and innovation across drug discovery, translational medicine, and biobanking. These gaps limit scientific progress because even the most sophisticated analytical tools depend on high-quality, well-characterised human biological specimens. This custom eBook for BioIVT explores the… Read More

#eBooks

Robotic arm, automation
#Automation / robotics #Events #Lab technology #SLAS2026

Expert discusses interoperable automation DDW SLAS2026 track

Kelly Bachovchin PhD, Customer Engagement Scientist, Collaborative Communications, will be speaking at the DDW track Creating Cures: The role of lab automation in successful drug discovery at SLAS2026. He will discuss Interoperable Automation: Real-Time Dataflows to Close DMTA Cycles. You… Read More

#News

Cell engineering
#DDW Turning Science into Business Symposium #Drug discovery #Events

Did you miss the DDW Symposium? Watch now on-demand

If you missed the DDW Turning Science into Business Symposium, you can now watch it on-demand here.  The event, which combined the latest drug discovery science and technology with market insight, took place at the Francis Crick Institute, London, UK on 4 November 2025. … Read More

#News

Automation and robotics
#Artificial intelligence (AI) #Automation #Drug discovery #Webinar

Webinar: How AI Agents transform day-to-day scientific work

AI has reached a turning point in biotech. Real-world scientific agents are beginning to automate the repetitive tasks that slow down research, and transform how we think about extracting insights from scientific data. In this webinar on… Read More

Webinar date:
Supported by Benchling
#News

Metabolomics
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Webinar

Webinar: Leveraging untargeted metabolomics and lipidomics

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Tower Bridge, London
#Drug discovery #Events #Investment #London Life Sciences Week #Market reporting

‘Good vibrations’ at London Life Science Week bode well for 2026

Jefferies’ Global Healthcare Conference held every November and coinciding with London Life Science Week (LLSW), is staking its claim as one of the world’s ‘must attend’ biotech investor events – and a vital barometer going into the New Year. DDW found the atmosphere refreshingly upbeat.  “Going into… Read More

#Exclusive Content #Trends & Analysis

#Awards #Drug discovery #Metabolomics

$30,000 award up for grabs in metabolomics research 

Biotechnology company NADMED has launched an award worth $30,000 to accelerate breakthroughs in metabolomics research.  The NADMED Award 2026 is a global initiative designed to empower scientific discovery in redox biology and accelerate innovation across medicine, life sciences, and biotechnology. The award aims to enable scientists and clinicians… Read More

#News

Cell and gene therapy
#Advanced Therapies #Cell and gene therapy #Drug development #NHS

eXmoor and NHS trust partner on cell & gene therapies 

Cell and gene therapy CDMO eXmoor Pharma has partnered with Royal Free London NHS Foundation Trust to collaborate on the development and manufacturing of cell and gene therapies in the UK. The collaboration brings together eXmoor’s later-phase clinical manufacturing capabilities  with the trust’s Cell and Vector Innovation Centre (CVIC), which… Read More

#Business & Investment #News

Lab automation
#Automation / robotics #Events #Lab technology #SLAS2026

AstraZeneca drug discovery expert joins DDW track at SLAS2026

Mel Leveridge, Vice President, Assays, Profiling & Cell Sciences, AstraZeneca will be speaking at the DDW track Creating Cures: The role of lab automation in successful drug discovery at SLAS2026. Mel Leveridge, Vice President, Assays, Profiling & Cell Sciences, AstraZeneca. She will discuss The Role of… Read More

#News